The effectiveness of hormonal agents can vary depending on the type and stage of cancer. In many cases, they have significantly improved survival rates and quality of life. For instance, tamoxifen has been shown to reduce the risk of breast cancer recurrence by about 50% in ER-positive patients. Aromatase inhibitors have also been shown to be very effective in postmenopausal women with hormone-sensitive breast cancer.
